Posts for Ticker ‘AUXL’

Auxilium Scores on Pfizer Pact (AUXL, PFE)

Money_stack_pic_2Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) is responding well in pre-market trading after the company signed an overseas commercialization agreement with Pfizer, Inc. (NYSE: PFE).  The pact covers Auxilium’s Xiaflex, a treatment for hand and urological disorders related to hardening collagen.

Read More »

Posted on: December 18, 2008 – 8:31 am in Biotech, Drug companies, ,

Early Bird Pre-Market Analyst Upgrades (ALB, AUXL, BIIB, CBEY, HAIN, HWD, LVS, SYMC, TEVA, TWTC, WBSN, WFMI)

These are some of the early bird analyst upgrades and positive calls we are seeing this Thursday morning with more than two hours to the open:

  • Auxilium Pharma (AUXL) Started as Outperform at Oppenheimer.
  • Biogen-Idec (BIIB) Started as Buy at Stanford Group.
  • CBeyond (CBEY) Started as Buy at SunTrust Robinson Humphrey.
  • Hain Celestial (HAIN) Started as Buy at Jefferies.
  • Harry Winston Diamond (HWD) Raised to Overweight at Thomas Weisel.
  • Las Vegas Sands (LVS) Raised to Hold at KeyBanc.
  • Symantec (SYMC) Started as Buy at B of A.
  • Teva Pharma (TEVA) Started as Outperform at Oppenheimer.
  • TW Telecom (TWTC) Started as Buy at SunTrust Robinson Humphrey.
  • Websense (WBSN) Started as Buy at B of A.
  • Whole Foods (WFMI) Started as Buy at Jefferies.

Jon C. Ogg
September 11, 2008

Posted on: September 11, 2008 – 6:23 am in Analyst Calls, , , , , , , , , , ,

The Week’s Top Biotech Movers For Next Week (TRCA, ACOR, ISPH, ONCY, PCYC, SQNM, IDEV, LGND, AUXL)

Out of the daily movers this last week, many of the top winners and losers were from news in many of the smaller biotech stocks.  We prepared a list of the winners and sinners from our daily review at BioHealthInvestor.com and gave a summary regarding the moves on each.  It is becoming more obvious that many small and mid-sized biotechs are going to be gobbled up by European or Asian biotech and pharma companies seeking the dollar-discount right now.

For starters, we ran a summary of the key moving pieces out of the American Society of Clinical Oncology (ASCO).  No review would be complete without it. Stocks covered: (AVAN, PFE, CELG, IMCL, DNA)

ACQUISITION NEWS
Tercica, Inc. (NASDAQ: TRCA) bites the dust as its own company the latest small cap biotech received a huge premium acquisition from a foreign buyer, with a 104% premium.  FULL DETAILS

MAJOR WINNERS
Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients’ walking abilities in MS patients.  FULL DETAILS

Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) surged after reaching its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis.  FULL DETAILS

Oncolytics Biotech Inc. (NASDAQ: ONCY) gained after the Canadian biotech’s positive Phase II studies of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung.  FULL DETAILS

Pharmacyclics Inc. (NASDAQ: PCYC) gained after its Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy showed a high complete response rate in patients with non-Hodgkin’s lymphoma.  FULL DETAILS

Sequenom Inc. (NASDAQ: SQNM) surged after it announced its progress with a non-invasive technology that detects Down syndrome. FULL DETAILS

MAJOR LOSERS
Indevus Pharmaceuticals Inc. (NASDAQ: IDEV) tanked after an FDA request should cause a two-year delay in approving NEBIDO.  FULL DETAILS

MIXED REVIEW
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is one we gave a full pro and con review covering the upside of the stock and the negative side of the stock.  FULL DETAILS

Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week.  The company reported great news but shares slid before the market figured out it had misinterpreted news in the company.  INITIAL DETAILS

Jon C. Ogg
June 7, 2008

Posted on: June 7, 2008 – 6:01 am in Biotech, The Week, , , , , , , , ,

George Soros Top Equity Holdings (AAPL, AUXL, BFLY, CBI, CMG, CRUS, COV, MAPP, POT, SVNT)

This week we got to see critical SEC filings showing holdings of many key and influential investors.  Included in these filings were billionaire George Soros, a billionaire whom is loved by some and much less ‘well thought of’ by others over his currency trading history of over his MoveOn.org attempts.  Either way, investors still watch Soros.  These are the holdings of Soros Fund Management LLC as of December 31, 2007.  These were listed as the top holdings and are not at all his entire positions.  Soros Fund Management LLC was listed as having some $2.269 Billion in the total filing, and these positions here only equate to $360+ million, so there are many more positions.  As with all of these holdings, these positions may have changed or been eliminated as of the dates noted.  Here is a summary of his larger positions with a dollar amount provided by Soros as filer and a share count:

  • Apple Inc. (NASDAQ: AAPL)   $32,000,000;  161,550 shares
  • Auxilium Pharma (NASDAQ: AUXL)   $36,473,000;  1,216,180 shares
  • Bluefly Inc. (NASDAQ: BFLY)   $36,451,000;  48,601,156 shares… an old favorite of his…
  • Chicago Bridge & Iron Co. (NYSE: CBI)   $29,743,000;  492,100 shares
  • Chipotle Mexican Grill, Inc. (NYSE: CMG)  $32,404,000;  220,332 shares
  • Cirrus Logic Inc. (NASDAQ: CRUS)   $24,376,000;  4,616,666 shares
  • Covidien, Ltd. (NYSE: COV)   $32,194,000;  726,900 shares
  • MAP Pharmaceuticals (NASDAQ: MAPP)   $71,374,000;  4,076,169
  • Potash Corp. (NYSE: POT)   $37,933,000;  263,500 shares
  • Savient Pharmaceuticals (NASDAQ: SVNT)   $25,002,000;  1,088,461 shares

As Soros himself says …."Contrary to the tenets of market fundamentalism, financial markets do not tend towards equilibrium; they are crisis prone."   

Other billionaires and their holdings filed this week:
Bill Gates
Carl Icahn
Warren Buffett

Jon C. Ogg
February 16, 2008

Posted on: February 16, 2008 – 9:17 am in Insider Activity, , , , , , , , , ,